Thus, there is an urgent need to develop a longer half-life ATRA formulation or Pin1-targeted ATRA derivatives or more specific Pin1 inhibitors for treating non-APL leukemia and other cancers. The gene discussed is PIN1; the disease is acute promyelocytic leukemia.